[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353797-105":59,"doc-detail-353797-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","co-expression-of-pkc-and-aldh1a3-is-associated-with-poor-chemotherapeutic-responses-in-basal-like-breast-cancer","Co-expression of PKCζ and ALDH1A3 Is Associated With Poor Chemotherapeutic Responses in Basal-like Breast Cancer","","Study examines how co-expression of protein kinase C zeta (PKCζ) and the cancer stem cell–associated marker ALDH1A3 relates to chemotherapy outcomes in breast cancer subtypes. METABRIC (n=2,509) and TCGA Pan-Cancer Atlas (n=1,084) datasets are analyzed using Kaplan–Meier and Cox proportional hazards models. High PKCζ predicts poor disease-specific survival, particularly in basal-like tumors receiving cyclophosphamide, and combined PKCζhigh/ALDH1A3high basal-like disease shows the worst survival across key chemotherapy agents. PKCζ/ALDH1A3 also suggests potential prognostic value.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/co-expression-of-pkc-and-aldh1a3-is-associated-with-poor-chemotherapeutic-responses-in-basal-like-breast-cancer/353797/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/co-expression-of-pkc-and-aldh1a3-is-associated-with-poor-chemotherapeutic-responses-in-basal-like-breast-cancer/353797.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What question does the study address regarding PKCζ and ALDH1A3?","Question",{"text":113,"@type":114},"It investigates whether PKCζ expression and ALDH1A3 expression jointly relate to disease-specific survival and chemotherapy responses across breast cancer subtypes, with special attention to cancer stem cell–associated ALDH1A3.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which datasets and statistical methods are used to evaluate the associations?",{"text":118,"@type":114},"The study analyzes METABRIC (n=2,509) with Kaplan–Meier survival curves and Cox proportional hazards models, and validates findings using TCGA Pan-Cancer Atlas (n=1,084).",{"name":120,"@type":111,"acceptedAnswer":121},"What is the main finding about combined PKCζhigh/ALDH1A3high basal-like tumors?",{"text":122,"@type":114},"Patients with high expression of both PKCζ and ALDH1A3 in basal-like tumors treated with cyclophosphamide, doxorubicin, or fluorouracil show the worst disease-specific survival compared with other groups, and anthracycline- or taxane-based regimens also correspond to poorer prognosis.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},353797,1790421151,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":31,"preview_page_count":19,"preview_urls":145},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","doi: 10.21873/cgp.20579  \nCo-expression of PKCζ and ALDH1A3 Is Associated With Poor Chemotherapeutic Responses  \nin Basal-like Breast Cancer  \nYUKA NAGASHIMA1*, MEGUMIOGINO1*, RANMANOKIYAMA1, RYOSUKE CHIWAKI1,2, HAYATO ISHII1, KANA NOHATA1, AYAKA NAKAHARA1, AYAKA OZAKI1, TAKAHIRO KASAI1, SHOMATAMORI1,3, SHIGEO OHNO2, KAZUNORI SASAKI2 and KAZUNORI AKIMOTO1,3  \n1 Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan;  \n2 Laboratory of Cancer Biology, Institute for Diseases of Old Age, Juntendo University School of Medicine, Tokyo, Japan; 3 Research Division of Medical Data Science, Research Institute for Science and Technology,  \nTokyo University of Science, Chiba, Japan  \nAbstract  \nBackground/Aim: The association between the expression of protein kinase C zeta (PKCζ) and chemotherapeutic responses among different subtypes of breast cancer has yet to be fully elucidated. The present study aimed to investigate the association between PKCζ expression and disease‑specific survival (DSS) rates, with a particular focus on the influence of chemotherapy and cancer stem cell (CSC)‑associated ALDH1A3 expression.  \nMaterials and Methods: Clinical and gene expression data from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) dataset (n=2,509) were analyzed using Kaplan‑Meier and Cox proportional hazards models. The findings were validated using The Cancer Genome Atlas (TCGA) Pan‑Cancer Atlas dataset (n=1,084) .  \nResults: In the METABRIC dataset, high PKCζ expression (PKCζhigh) was associated with poor DSS rates inpatients with the normal‑like, claudin‑low and basal‑like subtypes treated with chemotherapy. Consistent results were obtained in TCGA dataset, where PKCζhigh expression in basal‑like breast cancer predicted poor prognosis, especially among patients treated with cyclophosphamide, analkylating agent. Combined analysis further revealed that patients with high expression of both PKCζand ALDH1A3(PKCζhigh/ALDH1A3high) basal‑like tumors treated with cyclophosphamide, doxorubicin, or fluorouracil had the worst DSS rates compared with other groups. In addition, PKCζhigh/ALDH1A3high basal‑like tumors treated with anthracycline‑ or taxane‑based regimens also exhibited poorer prognoses compared with other groups.  \ncontinued  \n*These Authors contributed equally to this study.  \nDr. Kazunori Akimoto, Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University  \noatfoSrcyieoncef Ca, Katsushncer Bioikloa‑kgy,uI,Tnokystituot1e2f5o‑85r Di85sea, Jsapesanof. TelOld: +8Ag1e,3J5876156untendo7U, e‑mnivearilsi:akimty Scohtooo@lrosf .tuMsed.ac.jicipne; ,DrB.Kunazkyuno‑oriku,SaTsoakkyi,o  \n113‑8421, Japan. Tel: +81 358021917, e‑[mail:](mail: k.sasaki.yb@juntendo.ac.jp)[ k.sasaki.yb@juntendo.ac.jp](mail: k.sasaki.yb@juntendo.ac.jp)  \nReceived November 23, 2025 | Revised December 25, 2025 | Accepted February 4, 2026  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n©2026 The Author(s) . Anticancer Research is published by the International Institute of Anticancer Research.  \nConclusion: PKCζ contributes to chemotherapeutic resistance, especially in patients withALDH1A3‑positive basal‑like breast cancer, possibly through the regulation of CSC survival and proliferation. Moreover, PKCζ, either alone or in combination withALDH1A3 expression, may serve as a prognostic biomarker for predicting the therapeutic efficacy of chemotherapy in basal‑like breast cancer.  \nKeywords: Basal‑like breast cancer, chemotherapy, ALDH1A3, PKCζ.  \nIntroduction  \nBreast cancer is the most common malignancy among women worldwide, and remains a leading cause of cancer‑associated death (1) . Standard treatment strategies typically include surgery, radiation therapy and systemic drug therapies, includ","cbCaiiALWbOli0xX","https://ap.wps.com/l/cbCaiiALWbOli0xX","pdf",3410792,"English","# Abstract\n## Background/Aim\n## Materials and Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What question does the study address regarding PKCζ and ALDH1A3?\",\"answer\":\"It investigates whether PKCζ expression and ALDH1A3 expression jointly relate to disease-specific survival and chemotherapy responses across breast cancer subtypes, with special attention to cancer stem cell–associated ALDH1A3.\"},{\"question\":\"Which datasets and statistical methods are used to evaluate the associations?\",\"answer\":\"The study analyzes METABRIC (n=2,509) with Kaplan–Meier survival curves and Cox proportional hazards models, and validates findings using TCGA Pan-Cancer Atlas (n=1,084).\"},{\"question\":\"What is the main finding about combined PKCζhigh/ALDH1A3high basal-like tumors?\",\"answer\":\"Patients with high expression of both PKCζ and ALDH1A3 in basal-like tumors treated with cyclophosphamide, doxorubicin, or fluorouracil show the worst disease-specific survival compared with other groups, and anthracycline- or taxane-based regimens also correspond to poorer prognosis.\"}]","Co-expression of PKCζ and ALDH1A3 Is Associated With Poor Chemotherapeutic Responses in Basal-like Breast Cancer | PDF",1790107291,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a43bd0661d68a9aad8f7bd151dd080d.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/71d88641b126567e1b3268ad467729fd.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52c2f199369765efd3ea3a9d47540f3c.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9ff5722110496734f46730919a58950c.webp",980,1306]